Omega Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	3.09	2.07	0.14	-	-
Revenue Growth (YoY)	49.25%	1339.58%	-	-	-
Cost of Revenue	65.87	77.27	47.87	21.06	-
Gross Profit	-62.78	-75.19	-47.72	-21.06	-
Selling, General & Admin	37.49	27.57	18.31	7.58	5.41
Research & Development	-	-	-	-	11.93
Operating Expenses	37.49	27.57	18.31	7.58	17.34
Operating Income	-100.26	-102.77	-66.03	-28.65	-17.34
Interest Expense	-1.8	-1.3	-1	-0.78	-0.6
Interest & Investment Income	4.61	1.52	0.09	0	-
Other Non Operating Income (Expenses)	0.02	-0.16	-1.34	-0.03	-0.01
Pretax Income	-97.43	-102.7	-68.28	-29.45	-17.95
Net Income	-97.43	-102.7	-68.28	-29.45	-17.95
Net Income to Common	-97.43	-102.7	-68.28	-29.45	-17.95
Shares Outstanding (Basic)	54	48	22	4	3
Shares Outstanding (Diluted)	54	48	22	4	3
Shares Change (YoY)	12.80%	113.72%	473.56%	17.69%	-
EPS (Basic)	-1.80	-2.14	-3.05	-7.54	-5.41
EPS (Diluted)	-1.80	-2.14	-3.05	-7.54	-5.41
Free Cash Flow	-94.38	-99.9	-59.08	-27.94	-16.56
Free Cash Flow Per Share	-1.75	-2.09	-2.64	-7.15	-4.99
Operating Margin	-3240.50%	-4957.36%	-45855.56%	-	-
Profit Margin	-3148.93%	-4954.22%	-47416.67%	-	-
Free Cash Flow Margin	-3050.39%	-4818.86%	-41025.00%	-	-
EBITDA	-98.69	-101.2	-64.65	-27.5	-16.55
D&A For EBITDA	1.57	1.56	1.39	1.15	0.79
EBIT	-100.26	-102.77	-66.03	-28.65	-17.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.